Download Free Medical Clinical trials in Europe PowerPoint Presentation

Clinical trials in Europe PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Drug Development, which is titled "Clinical trials in Europe", to know about Clinical Trials in Europe.

Tags : Drug Development, Clinical trials, Europe

Published on : Jul 20, 2021 | Views : 1042 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Professor Bruce Morland Birmingham, UK Clinical trials in Europe
Slide 2-

ppt slide no 2 content not found
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

ppt slide no 5 content not found
Slide 6-

Change of Paradigm in Oncology Drug Development& Era of High-throughput Technologies- When Biology Meets Clinics ….. ~ 1000 Anticancer compounds yearly under development Targeted anticancer compounds New mechanisms of action New profile of activity Distinct profile of toxicity Oral and prolonged administration
Slide 7-

SMO inhibition in Pediatric Patients Geoerger et al. ASCO 2012
Slide 8-

BRAFv600 inhibition in Pediatric Patients Primary Tumor Type Treatment Duration (Weeks) Kieran et al. ASCO 2015 HGG PTC NB LGG LCH ORR: HGG 5/8 63% anaplastic astrocytoma, glioma, ganglioglioma, pleomorphic xanthoastrocytoma, gliobastoma multiforme LGG 5/15 33% Ganglioglioma, pilocytic astrocytoma, pilomyxoid astrocytoma, pleomorphic xanthoastrocytoma LCH 2/2 100% Other 0% 20 of 27 patients remain on dabrafenib at data cut 7 March 2015
Slide 9-

Geoerger et al. ASCO 2015 ALK inhibition in ALK+ IMT or ALCL
Slide 10-

Hallmarks of Cancer
Slide 11-

Children small adults? Vogelstein et al., Science 2013 ≠
Slide 12-

Pediatric cancers are (relatively) simple … Courtesy of Stefan Pfister
Slide 13-

Discrepancies between primary and relapse Courtesy of Stefan Pfister
Slide 14-

MAPPYACTS (France, Spain, Italy, Ireland, Israel) 1. Generate invididual molecular information MATCH 2. Match treatment and tumor profile SHARE EU Clinico Biological (WES/RNAseq Data Base Project A Project B Project C Project D Project E 4. Generate new knowledge, new druggable pathways INFORM (Germany) iTHER (The Netherlands) SM-PAEDs (UK) Molecular Matching Trials Pediatric New Drug Development ESMART trial Multiarm Phase 1 Trials (Industry and ISTs) Phase 2 Trials (Industry and ISTs) 3. Evaluate activity of drugs and combinations Genentech Roche Matrix Trial Precision Medicine Program in ITCC INFORM2 trial series
Slide 15-

ppt slide no 15 content not found
Slide 16-

ppt slide no 16 content not found
Slide 17-

ppt slide no 17 content not found
Slide 18-

ppt slide no 18 content not found
Slide 19-

ppt slide no 19 content not found
Slide 20-

ppt slide no 20 content not found
Slide 21-

ppt slide no 21 content not found
Slide 22-

ppt slide no 22 content not found
Slide 23-

Drug availability is currently not a criterium in the pediatric setting (otherwise almost all targets would get a low score) Target prioritization – how to translate “gut feeling“ into a score!?
Slide 24-

ppt slide no 24 content not found
Slide 25-

ppt slide no 25 content not found
Slide 26-

ppt slide no 26 content not found
Slide 27-

ppt slide no 27 content not found
Slide 28-

ppt slide no 28 content not found
Slide 29-

ppt slide no 29 content not found
Slide 30-

MAPPYACTS (France, Spain, Italy, Ireland, Israel) 1. Generate invididual molecular information MATCH 2. Match treatment and tumor profile SHARE EU Clinico Biological (WES/RNAseq Data Base Project A Project B Project C Project D Project E 4. Generate new knowledge, new druggable pathways INFORM (Germany) iTHER (The Netherlands) SM-PAEDs (UK) Molecular Matching Trials Pediatric New Drug Development ESMART trial Multiarm Phase 1 Trials (Industry and ISTs) Phase 2 Trials (Industry and ISTs) 3. Evaluate activity of drugs and combinations Genentech Roche Matrix Trial Precision Medicine Program in ITCC INFORM2 trial series
Slide 31-

ppt slide no 31 content not found
Slide 32-

ppt slide no 32 content not found
Slide 33-

ppt slide no 33 content not found
Slide 34-

ppt slide no 34 content not found
Slide 35-

ppt slide no 35 content not found
Slide 36-

ppt slide no 36 content not found
Slide 37-

Ewing, rhabdo, neuroblastoma, Wilms, hepatoblastoma on backbone of temozolomide /irinotecan
Slide 38-

ppt slide no 38 content not found
Slide 39-

74 patients (median age 14 years; range 2–29) were enrolled: osteosarcoma, n = 12; Ewing sarcoma, n = 11; neuroblastoma, n = 11; rhabdomyosarcoma (RMS), n = 10; non-RMS soft tissue sarcoma, n = 10; Wilms tumor, n = 6; Hodgkin lymphoma (HL), n = 5; non-HL, n = 1; other tumor types, n = 8 17 patients (24%) had treatment-related grade 3–4 AEs. One AE (grade 3 transaminase increase) led to study drug discontinuation. Common AEs were pyrexia (37%), fatigue (34%) and constipation (32%) 2/5 patients with HL had a partial response (PR); the only patient with atypical rhabdoid tumor (RT) had an unconfirmed PR Ongoing with rhabdoid/ATRT A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab). Geoerger et al. J Clin Oncol 35, 2017 (suppl; abstr 10524)
Slide 40-

Conclusions ITCC is a successful academic partnership Biology-led/precision medicine programme is deliverable Partnership/collaboration with Pharma is key Joint discussion with clinicians, regulators, pharma and parent groups, Accelerate has proven very successful (www.accelerate-platform.eu) Portfolio expanding
Slide 41-

ppt slide no 41 content not found
Slide 42-

ppt slide no 42 content not found
Slide 43-

תודה